STRIDER NZAus:西地那非治疗早发型胎儿生长受限的多中心随机对照试验
在新西兰和澳大利亚13个母胎医学单位开展的随机安慰剂对照试验,纳入22+0至29+6周单胎早发型胎儿生长受限孕妇,口服西地那非25 mg每日三次至32+0周、分娩或胎死。西地那非未影响胎儿生长速度增加的比例(52.5% vs 68.4%,校正OR 0.49,95%CI 0.23-1.05),也未影响腹围Z评分(P=0.61)。
要点
- 西地那非未影响胎儿生长速度增加的比例:52.5% vs 68.4%,校正OR 0.49(95%CI 0.23-1.05)。
- 用药48小时后平均子宫动脉搏动指数较低:1.56 vs 1.81(P=0.02)。
- 活产、无主要新生儿疾病存活出院及新发子痫前期组间差异均未达统计学显著。
核心结论
- 母亲使用西地那非对胎儿生长速度无影响。
- 前瞻性计划的Meta分析将确定西地那非是否对母亲和胎儿/新生儿健康产生其他影响。
研究设计与样本
- 随机安慰剂对照试验,在新西兰和澳大利亚13个母胎医学单位开展。
- 研究对象为22+0至29+6周单胎妊娠合并胎儿生长受限的孕妇。
- 干预为口服西地那非枸橼酸盐25 mg或外观匹配的安慰剂,每日三次,至32+0周、分娩或胎死(以先发生者为准)。
主要发现
- 胎儿生长速度增加的比例:西地那非组32/61(52.5%)vs 安慰剂组39/57(68.4%),校正OR 0.49(95%CI 0.23-1.05)。
- 腹围Z评分:西地那非对腹围Z评分无影响(P=0.61)。
- 治疗48小时后平均子宫动脉搏动指数:西地那非组1.56 vs 安慰剂组1.81(P=0.02)。
- 活产率:西地那非组56/63(88.9%)vs 安慰剂组47/59(79.7%),校正OR 2.50(95%CI 0.80-7.79)。
- 无主要新生儿疾病存活出院:西地那非组42/63(66.7%)vs 安慰剂组33/59(55.9%),校正OR 1.93(95%CI 0.84-4.45);新发子痫前期:西地那非组9/51(17.7%)vs 安慰剂组14/55(25.5%),OR 0.67(95%CI 0.26-1.75)。
临床怎么用
- 原文结论为母亲使用西地那非对胎儿生长速度无影响,未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effect of maternal sildenafil therapy on fetal growth in pregnancies with early-onset fetal growth restriction. DESIGN: A randomised placebo-controlled trial. SETTING: Thirteen maternal-fetal medicine units across New Zealand and Australia. POPULATION: Women with singleton pregnancies affected by fetal growth restriction at 22+0 to 29+6 weeks. METHODS: Women were randomised to oral administration of 25 mg sildenafil citrate or visually matching placebo three times daily until 32+0 weeks, birth or fetal death (whichever occurred first). MAIN OUTCOME MEASURES: The primary outcome was the proportion of pregnancies with an increase in fetal growth velocity. Secondary outcomes included live birth, survival to hospital discharge free of major neonatal morbidity and pre-eclampsia. RESULTS: Sildenafil did not affect the proportion of pregnancies with an increase in fetal growth velocity; 32/61 (52.5%) sildenafil-treated, 39/57 (68.4%) placebo-treated [adjusted odds ratio (OR) 0.49, 95% CI 0.23-1.05] and had no effect on abdominal circumference Z-scores (P = 0.61). Sildenafil use was associated with a lower mean uterine artery pulsatility index after 48 hours of treatment (1.56 versus 1.81; P = 0.02). The live birth rate was 56/63 (88.9%) for sildenafil-treated and 47/59 (79.7%) for placebo-treated (adjusted OR 2.50, 95% CI 0.80-7.79); survival to hospital discharge free of major neonatal morbidity was 42/63 (66.7%) for sildenafil-treated and 33/59 (55.9%) for placebo-treated (adjusted OR 1.93, 95% CI 0.84-4.45); and new-onset pre-eclampsia was 9/51 (17.7%) for sildenafil-treated and 14/55 (25.5%) for placebo-treated (OR 0.67, 95% CI 0.26-1.75). CONCLUSIONS: Maternal sildenafil use had no effect on fetal growth velocity. Prospectively planned meta-analyses will determine whether sildenafil exerts other effects on maternal and fetal/neonatal wellbeing. TWEETABLE ABSTRACT: Maternal sildenafil use has no beneficial effect on growth in early-onset FGR, but also no evidence of harm.
引用
- Groom KM, McCowan LM, Mackay LK, et al. STRIDER NZAus: a multicentre randomised controlled trial of sildenafil therapy in early-onset fetal growth restriction. BJOG. 2019. PMID: 30779295. doi:10.1111/1471-0528.15658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。